Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00580242
Other study ID # 07-006
Secondary ID RV-MDS-PI-0161
Status Completed
Phase Phase 1
First received December 20, 2007
Last updated March 6, 2012
Start date November 2007
Est. completion date March 2012

Study information

Verified date March 2012
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination with lenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle for patients with myelodysplastic syndrome.


Description:

Currently, there are no curative therapies for myelodysplasia except for allogeneic stem cell transplantation. Both lenalidomide and bortezomib have activity as single agents in patients with myelodysplasia. This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination withlenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle. The planned bortezomib doses have been evaluated in previous Phase I clinical studies in similar patient populations and have been safe and well tolerated in a twice-weekly schedule of administration. Lenalidomide has been shown to have efficacy in myelodysplasia. The combination of lenalidomide and bortezomib has been used in patients with multiple myeloma.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients may be untreated or previously treated.

- Age > 18 years

- Able to adhere to study schedule and other protocol requirements

- Unequivocal clinicopathologic diagnosis of myelodysplastic syndrome, non 5q- deletion.

- Patients may have had prior chemotherapy or radiotherapy for another malignancy or myelodysplasia as long as it was completed at least 4 weeks (6 weeks for nitrosureas) prior to initiation of therapy.

- ECOG performance status of 0-2 (Appendix 10.3)

- Life expectancy greater than 3 months

- Total bilirubin = 2.0 mg/dl, ALT and AST = 3 X the upper limit of normal (ULN), creatinine < 2.0 mg/dl all within 28 days prior to enrollment.

- Patients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

- Absolute neutrophil count > 0.5 x 10 (9)/l

- Platelet count > 30 x 10 (9)/l

- Prior treatment with 5-azacytidine is encouraged, but not required.

- Patients may have had prior treatment for MDS, including single agent lenalidomide or bortezomib.

- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50mIU/ml within 10-14 days prior to and within 24 hours of prescribing lenalidomide and must commit to abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control,at least 4 weeks before starting taking lenalidomide. FCBP must agree to ongoing pregnancy testing. Men must agree not to father a child and agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy.

- All study participants must be registered into the mandatory RevAssist Program®, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria:

- Ejection fraction < 40%

- Patients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.

- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the consent form.

- Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

- Patients with major surgery within the 28 days prior to trial enrollment.

- Patients with = Grade 2 peripheral neuropathy or active herpes infection

- Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cirrhosis, chronic obstructive or restrictive pulmonary disease, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrythmia.

- Patients with secondary MDS that require concurrent therapy for the primary cancer diagnosis.

- The development of erythema nodosum as characterized by a desquamating rash while taking thalidomide or similar drugs.

- Patient with hypersensitivity to bortezomib, boron or mannitol.

- Female subject is pregnant or breast-feeding. . Lactating females must agree not to breast feed while taking lenalidomide.

- Patient has received an investigational drug within 28 days of enrollment.

- Known hypersensitivity to thalidomide or lenalidomide

- Concurrent use of other anti-cancer agents or treatments.

- Known positive for HIV

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Bortezomib
First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Bortezomib
Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Bortezomib
Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Lenalidomide
Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Massachusetts General Hospital Celgene Corporation, Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establish the maximally tolerated dose of bortezomib, up to 1.3 mg/m2/day, that can be administered in combination with lenalidomide in patients with primary and secondary non 5q del myelodysplasia who are untreated or previously treated. 3, 6 and 9 months No
Secondary Assess efficacy in terms of the number of patients experiencing a decrease in blast percentage 3, 6 and 9 months No
Secondary Assess efficacy in terms of the number of patients experiencing a decrease in transfusion requirements 3, 6 and 9 months No
Secondary Determine the toxicity profile of bortezomib when used in combination with lenalidomide for patients with myelodysplasia 3, 6 and 9 months Yes
Secondary Determine the time (days) to transfusion independence 3, 6 and 9 months No
Secondary Determine the duration of response 3, 6 and 9 months No
Secondary Determine if molecular markers can predict responsiveness to treatment (for consenting patients) 3, 6 and 9 months Yes
See also
  Status Clinical Trial Phase
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Recruiting NCT02323867 - Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies Phase 2
Completed NCT01933035 - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. N/A
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Recruiting NCT04202835 - ATG Plus PTCy vs ATG for CGVHD Prophylaxis Phase 2
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Completed NCT00516152 - Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Phase 2
Completed NCT01956799 - Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Terminated NCT00109538 - Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Phase 3
Completed NCT00578942 - Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Active, not recruiting NCT00899223 - Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
Recruiting NCT04800458 - Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis N/A
Recruiting NCT05735717 - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Phase 2
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A